Kintor Pharmaceutical Limited

Equities

9939

KYG5273B1077

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:16 2024-05-02 am EDT			5-day change	1st Jan Change
1.06 ^HKD	+13.98%		+10.42%	-34.97%

Apr. 22	Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint	CI
Apr. 22	Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment	MT

Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2023

August 28, 2023 at 08:32 am EDT

Kintor Pharmaceutical Limited reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was CNY 212.11 million compared to CNY 518.42 million a year ago. Basic loss per share from continuing operations was CNY 0.5 compared to CNY 1.42 a year ago.

Latest news about Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint	Apr. 21	CI
Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment	Apr. 21	MT
Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Kintor Pharmaceutical's Trial of Androgenetic Alopecia Drug Cleared by Chinese Regulator	Feb. 01	MT
Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA	Feb. 01	CI
Kintor Pharmaceutical's Phase 3 Trial for Alopecia Treatment Promotes Hair Growth; Shares Plunge 30%	Nov. 26	MT
Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia	Nov. 26	CI
Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China	23-10-11	CI
Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Kintor Pharmaceutical Completes Enrollment for Alopecia Drug Trial	23-08-23	MT
Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China	23-08-22	CI
Kintor Pharmaceutical Enrolls First Patient for Phase III of Alopecia Drug Trial	23-07-20	MT
Kintor Pharmaceutical Limited Announces Completion of First Patient Enrollment in Long-Term Safety Trial of Kx-826	23-07-19	CI
Kintor Pharmaceutical Limited Appoints Ming Ming Cheung as Joint Company Secretary	23-05-12	CI
Kintor Pharmaceutical's Completes US Phase 2 Trials of Alopecia Treatment; Shares Fall 4%	23-05-12	MT
Kintor Pharmaceutical Limited Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US	23-05-11	CI
Kintor Pharmaceutical Completes Phase I Trial of Drug Treating Hematologic Malignancies	23-05-08	MT
Kintor Pharmaceutical Limited Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematological Malignancies in China	23-05-08	CI
Kintor Pharma Enrols First Subject for Alopecia Treatment Phase 2 Clinical Trial	23-04-14	MT
Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Phase II Clinical Trial of AR-PROTAC (GT20029 ) for Treatment of Men Androgenetic Alopecia in China	23-04-14	CI
Kintor Pharmaceutical Limited Announces Management Changes	23-04-14	CI
Kintor Pharmaceutical Limited Announces Chief Financial Officer Changes	23-04-14	CI
Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China	23-03-28	CI
Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia and Acne Presented at AAD 2023	23-03-21	CI

Chart Kintor Pharmaceutical Limited

Duration

Period

More charts

Company Profile

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China. The Company is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The Company are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.

Sector

Biotechnology & Medical Research

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8607 CNY

Average target price

13.21 CNY

Spread / Average Target

+1,434.85%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KINTOR PHARMACEUTICAL LIMITED	-34.97%	53.19M
VERTEX PHARMACEUTICALS INCORPORATED	-1.36%	104B
REGENERON PHARMACEUTICALS, INC.	+5.12%	97.47B
ARGENX SE	+5.71%	22.25B
BIONTECH SE	-13.52%	21.68B
GENMAB A/S	-9.70%	18.2B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-11.00%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+8.73%	14.39B
SAREPTA THERAPEUTICS, INC.	+40.39%	12.37B

Bio Therapeutic Drugs